• BioInfra listed on KOSDAQ market   [Mar 02, 2023]  BioInfra was listed on KOSDAQ market on March 2. Original article published on Yonhapnews Agency. 
• BioInfra aims to become the world's leading phase I clinical trial company.     [Feb 15, 2023] At the Biz invitation today, I met Lee Sang-deuk, CEO of BioInfras co., Ltd., a phase 1 clinical company that challenged the KOSDAQ market again.BioInfra is a c..
• BioInfra wins Korea Value Management Award 2022  [Nov 23, 2022] BioInfra wins Korea Value Management Award 2022.Korea Value Management Awards are given to companies that derive new added value and corporate growth engines through innovati..
• BioInfra’s 16th Business Report  We published our 16th business report. You can see it in the link below or download the attachment.
• In the first half of 2023, many biotech companies try to list on the stock market again.  [Feb 08, 2023] Many biotech companies are preparing for initial public offerings in the first half of this year.When we examine these companies, “Gwontojungrae” becomes trend in biotec..
• BioInfra secures global market on BE reliability [Nov 23, 2022] BioInfra Co., Ltd., a contract research organization specialized in phase 1 clinical trials, will expand its business area based on analysis system technology. Original articl..
• Challenge to breakthrough IPO  [Nov 14, 2022] There is another small company that is challenging to be listed on the stock market this month. It is BioInfra Co.,Ltd, a contract research organization(CRO) company.Ori..
• BioInfra passes KOSDAQ eligibility [Oct 13, 2022] The KOSDAQ Market division of the Korea Exchange announced on October 13 that it had approved the eligibility review for listing of Bioinfra Co., Ltd. Original article pu..